Virios Therapeutics (VIRI) Competitors $2.60 +0.75 (+40.54%) (As of 11/19/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends VIRI vs. NGNE, EDIT, CRBP, OPT, ENTA, ADCT, ZURA, CMPX, HRTX, and TNYAShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Neurogene (NGNE), Editas Medicine (EDIT), Corbus Pharmaceuticals (CRBP), Opthea (OPT), Enanta Pharmaceuticals (ENTA), ADC Therapeutics (ADCT), Zura Bio (ZURA), Compass Therapeutics (CMPX), Heron Therapeutics (HRTX), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Neurogene Editas Medicine Corbus Pharmaceuticals Opthea Enanta Pharmaceuticals ADC Therapeutics Zura Bio Compass Therapeutics Heron Therapeutics Tenaya Therapeutics Virios Therapeutics (NASDAQ:VIRI) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment and dividends. Does the media prefer VIRI or NGNE? In the previous week, Neurogene had 15 more articles in the media than Virios Therapeutics. MarketBeat recorded 18 mentions for Neurogene and 3 mentions for Virios Therapeutics. Neurogene's average media sentiment score of 0.31 beat Virios Therapeutics' score of -0.13 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virios Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neurogene 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community prefer VIRI or NGNE? Neurogene received 22 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Neurogene an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% NeurogeneOutperform Votes25100.00% Underperform VotesNo Votes Do analysts prefer VIRI or NGNE? Virios Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 15.38%. Neurogene has a consensus target price of $60.83, indicating a potential upside of 296.83%. Given Neurogene's stronger consensus rating and higher probable upside, analysts clearly believe Neurogene is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Neurogene 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is VIRI or NGNE more profitable? Neurogene's return on equity of -32.44% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Neurogene N/A -32.44%-27.70% Which has more volatility & risk, VIRI or NGNE? Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Which has better earnings and valuation, VIRI or NGNE? Virios Therapeutics has higher earnings, but lower revenue than Neurogene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-9.63Neurogene$925K215.35-$36.32MN/AN/A Do institutionals & insiders have more ownership in VIRI or NGNE? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 9.9% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryNeurogene beats Virios Therapeutics on 12 of the 15 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.07M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-9.6310.57134.3717.77Price / SalesN/A243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book13.005.474.674.68Net Income-$5.30M$153.61M$119.07M$226.08M7 Day Performance-12.46%-2.00%-1.83%-1.04%1 Month Performance-34.18%-7.47%-3.62%1.04%1 Year Performance281.23%31.80%31.63%26.28% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios Therapeutics0.741 of 5 stars$2.60+40.5%$3.00+15.4%+254.9%$50.07MN/A-9.635Gap DownNGNENeurogene2.9326 of 5 stars$15.33-11.0%$60.83+296.8%N/A$199.20M$925,000.000.0090Analyst ForecastHigh Trading VolumeEDITEditas Medicine4.7809 of 5 stars$2.41-2.8%$9.08+276.9%-77.8%$198.95M$78.12M-0.96230Short Interest ↓CRBPCorbus Pharmaceuticals4.8769 of 5 stars$16.08-2.9%$65.86+309.6%+249.6%$195.85M$880,000.00-3.4340Positive NewsOPTOpthea2.051 of 5 stars$3.31+1.5%$12.00+262.5%+72.4%$193.29M$124,666.000.008ENTAEnanta Pharmaceuticals3.6551 of 5 stars$9.08-3.6%$20.00+120.3%+1.6%$192.41M$79.20M-1.73145ADCTADC Therapeutics2.8856 of 5 stars$1.98-3.9%$8.25+317.7%+177.9%$190.96M$70.72M-0.83310Positive NewsZURAZura Bio3.9024 of 5 stars$2.90-7.9%$15.80+444.8%-35.1%$189.34MN/A0.003Analyst ForecastCMPXCompass Therapeutics3.4259 of 5 stars$1.37-3.5%$6.75+392.7%-18.9%$188.50M$850,000.00-3.7020HRTXHeron Therapeutics3.9719 of 5 stars$1.12-5.9%$5.67+406.0%-13.8%$180.99M$137.74M-6.22300Analyst DowngradeShort Interest ↓TNYATenaya Therapeutics3.9666 of 5 stars$2.22-2.2%$14.75+564.4%+18.4%$179.83MN/A0.00110Gap Up Related Companies and Tools Related Companies Neurogene Alternatives Editas Medicine Alternatives Corbus Pharmaceuticals Alternatives Opthea Alternatives Enanta Pharmaceuticals Alternatives ADC Therapeutics Alternatives Zura Bio Alternatives Compass Therapeutics Alternatives Heron Therapeutics Alternatives Tenaya Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VIRI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIRI Stock Alerts